Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2018
Price : $35 *
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Chronic heart failure; Iron deficiency anaemia
- Focus Pharmacodynamics; Pharmacogenomic
- 29 Oct 2018 Status changed from recruiting to discontinued.
- 25 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 18 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.